Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maghan Ashmore

Nurse Practitioner, Primary Care Cleveland, MS Nurse Practitioner

NPI 1720624430 CMS profile 11119014

810 E Sunflower Rd Ste 100A, Cleveland, MS 38732

Open in the dashboard

General payments

$1,981

119 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maghan Ashmore of Cleveland, MS is reported in the CMS Open Payments database as having received $1,981 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $460 23
2024 General $580 35
2023 General $339 22
2022 General $210 12
2021 General $392 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maghan Ashmore
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Maghan Ashmore were reported at $460. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Maghan Ashmore Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $392 $137 $39–$445 $132
2022 $210 $139 $44–$421 $149
2023 $339 $163 $53–$481 $160
2024 $580 $176 $54–$511 $164
2025 $460 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $634 44 payments
  2. Lilly USA, LLC $186 11 payments
  3. Pfizer Inc. $169 10 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $128 8 payments
  5. AbbVie, Inc. $121 6 payments
  6. AstraZeneca Pharmaceuticals LP $114 8 payments
  7. Dexcom, Inc. $93 5 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $85 5 payments
  9. Alpha Cognition USA, Inc. $68 1 payment
  10. GlaxoSmithKline, LLC. $61 4 payments
  11. Other $322 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,981 119 payments
Products named General payments · program years 2021–2025
  1. Ozempic $541 36 payments
  2. RYBELSUS $541 36 payments
  3. NURTEC ODT $169 10 payments
  4. Kerendia $128 8 payments
  5. Tresiba $124 9 payments
  6. ZAVZPRET $117 7 payments
  7. MOUNJARO $102 6 payments
  8. JARDIANCE $84 5 payments
  9. Dexcom G6 Transmitter $76 4 payments
  10. FARXIGA $69 5 payments
  11. Other $1,211 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 85 drugs

Part D claims

2,915

Median for Nurse Practitioner: 389

Drug cost

$211,669

Median for Nurse Practitioner: $21,885

Branded share of claims

16%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 52 $54,729
Ozempic Semaglutide Brand 24 $33,481
Farxiga Dapagliflozin Propanediol Brand 31 $27,564
Jardiance Empagliflozin Brand 31 $23,729
Linzess Linaclotide Brand 29 $21,829
Tresiba Flextouch U-200 Insulin Degludec Brand 17 $17,118
Olmesartan Medoxomil Generic 105 $1,565
Esomeprazole Magnesium Generic 45 $1,558
Fentanyl Generic 12 $1,450
Clonidine Generic 16 $1,424

The 10 drugs with the highest cost, of 85 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$107,435

Of which drugs: $33,376

Medicare patients

487

Average age 76

Services billed

8,569

310 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 41%
Ischemic heart disease 27%
Heart failure 25%
Chronic kidney disease 25%
COPD 23%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 17 1,200 $25,143
Vaccine for influenza for injection into muscle 90653 Office 51 51 $4,091
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 97 120 $572
Injection, lincomycin hcl, up to 300 mg J2010 Office 56 63 $399
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 68 130 $104
Injection, ketorolac tromethamine, per 15 mg J1885 Office 28 122 $63
Injection, ceftriaxone sodium, per 250 mg J0696 Office 20 100 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $86
$86 — —
Ozempic
  • Novo Nordisk Inc $86
$86 24 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $49
$49 — —
NURTEC ODT
  • PFIZER INC. $44
$44 — —
ZAVZPRET
  • PFIZER INC. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record